Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyverna Therapeutics, Inc. (KYTX : NSDQ)

• Company Description    Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif. Number of Employees: 112

• Price / Volume Information    Yesterday's Closing Price: $6.58 Daily Weekly Monthly 20 Day Moving Average: 687,023 shares Shares Outstanding: 43.25 (millions) Market Capitalization: $284.56 (millions) Beta: 3.78 52 Week High: $8.45 52 Week Low: $1.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.75% -3.35% 12 Week 87.46% 79.69% Year To Date 75.94% 53.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 HORTON STREET SUITE 550 - EMERYVILLE,CA 94608 USA ph: 510-626-8331 fax: - investorrelations@kyvernatx.com https://kyvernatx.com

• General Corporate Information    Officers Warner Biddle - Chief Executive Officer and Director Ryan Jones - Chief Financial Officer Ian Clark - Director Fred E. Cohen - Director Mert Aktar - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501976104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 43.25 Most Recent Split Date: (:1) Beta: 3.78 Market Capitalization: $284.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -44.78% vs. Previous Quarter: 5.83% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -64.98 03/31/25 - -51.66 ROA 09/30/25 - - 06/30/25 - -56.17 03/31/25 - -45.92 Current Ratio 09/30/25 - - 06/30/25 - 5.39 03/31/25 - 7.44 Quick Ratio 09/30/25 - - 06/30/25 - 5.39 03/31/25 - 7.44 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.27 03/31/25 - 5.18 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.01 03/31/25 - 0.03

Powered by Zacks Investment Research ©